Novo, Wegovy and MAS
Digest more
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis but without cirrhosis.
The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on Friday. Roughly 15 million people — six percent of adults in the United States — have metabolic dysfunction-associated steatohepatitis, known as MASH. Rates of the disease are rising.
Zacks.com on MSN2h
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain
NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should benefit from this trend.
Health and Me on MSN11h
Wegovy Approved For MASH Treatment With Fibrosis But No Cirrhosis
FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated steatohepatitis (MASH) in adults. Know how the approval was given and what it means for Wegovy's future as a weightloss and diabetes drugs.
The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to advanced liver fibrosis but no cirrhosis, to be given as a once-weekly, 2.4-mg subcutaneous injection alongside diet and exercise, drugmaker Novo Nordisk noted.
Novo Nordisk makes the wildly popular GLP-1 drug semaglutide which it sells under the brand name Wegovy for weight-loss and Ozempic for diabetes.
Feedback